ClinicalTrials.gg
CompletedNCT01081041Updated Sep 25, 2019Results posted

A Study in Head and Neck Cancer

A Phase 2 interventional study of Cetuximab and Cisplatin in Head and Neck Cancer, sponsored by Eli Lilly and Company. Completed at 26 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-25.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
187
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies testing cetuximab in Head and Neck Neoplasms — 2 open to participants now, 7 under way, 2 of them phase 3. Cetuximab · Head and Neck Neoplasms.

Enrollment
6th of 84
187 · median 37
Started
2010
with 11 others
Phase 2
52 of 86
1 open now
Registered
47th of 86
by date
Lead sponsor
5 of 86
Eli Lilly and Company

Among the 86 studies testing cetuximab in Head and Neck Neoplasms, this one is the 6th largest by enrollment of the 84 interventional ones that give a count, is one of 12 that started in 2010, is one of 52 in phase 2, and was the 47th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

2 of the 86 studies testing cetuximab in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cetuximab

Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing cetuximab in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

This study will begin with a 30 participant lead-in part: these 30 participants will receive cetuximab manufactured by ImClone on a weekly basis in combination with other chemotherapy drugs [cisplatin or carboplatin plus 5-fluorouracil (5-FU)] administered every 3 weeks. After 18 weeks, participants who benefit from this treatment may continue to receive cetuximab once-weekly until progression of the disease, an unacceptable side effect occurs, participants withdraw consent, or the study is closed.

In the second part of this study, 200 participants will be randomized in 2 arms:

  • 100 participants will receive commercial cetuximab manufactured by ImClone (Group A)
  • 100 participants will receive cetuximab manufactured by Boehringer Ingelheim (Group B).

All these 200 participants will receive other chemotherapy drugs (cisplatin or carboplatin plus 5-FU) administered every 3 weeks. After 18 weeks, participants who benefit from this treatment may continue to receive cetuximab once-weekly until progression of the disease, an unacceptable side effect occurs, participants withdraw consent, or the study is closed.

03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Head and neck cancer that was confirmed by tissue or cytology
  • Disease not suitable for local therapy
  • Measurable or evaluable disease
  • performance status (KPS) score of at least 70
  • Organs are functioning well (bone marrow reserve, liver and kidney)
  • of at least 12 weeks
  • Signed document

Exclusion criteria

Exclusion Criteria:

  • Receiving another medication within the last 30 days
  • Prior chemotherapy, except if given as part of a multimodal treatment for locally advanced head and neck cancer that was completed more than 4 months prior to study entry.
  • Nasopharyngeal carcinoma
  • Previous treatment with monoclonal antibody therapy or other signal transduction inhibitors or epidermal growth factor receptor (EGFR) targeting therapy except for prior cetuximab treatment given as part of a multimodal treatment for locally advanced head and neck cancer that was completed more than 4 months prior to study entry.
  • Uncontrolled high blood pressure
  • Heart disease or had a heart attack within the last year
  • Currently have an infection that requires for you to take an IV antibiotic
  • Currently receiving other therapies for your cancer, such as chemotherapy, radiation therapy, immunotherapy, and hormonal therapy
  • Medical or psychological condition that would not permit the participant to complete the study or sign
  • Known drug abuse (with the exception of alcohol abuse)
  • Known allergic reaction against any of the components of the study treatment
  • Second primary that is clinically detectable at the time of consideration for study enrollment
  • Have had another type of cancer within the last 2 years
  • You are currently pregnant or breastfeeding
  • You are considering becoming pregnant or fathering a child
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
187 participants (actual)

Study arms

  • Experimental
    Safety Lead-In (cetuximab manufactured by ImClone)

    Cycle 1: Week 1 - Cetuximab 400 milligrams per square meter (mg/m\^2) on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin area under the curve (AUC) 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met.

    Drug: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Cetuximab manufactured by ImClone

    Cycle 1: Week 1 - Cetuximab 400 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met.

    Drug: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

  • Experimental
    Cetuximab manufactured by Boehringer Ingelheim

    Cycle 1: Week 1 - Cetuximab 400 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 Cycle 2-6: Week 1 - Cetuximab 250 mg/m\^2 on Day 1; Cisplatin 100 mg/m\^2 on Day 1 or carboplatin AUC 5 on Day 1; 5-FU 1000 mg/m\^2 on Days 1-4 Week 2 - Cetuximab 250 mg/m\^2 on Day 1 Week 3 - Cetuximab 250 mg/m\^2 on Day 1 After 6 cycles, participants may then receive weekly cetuximab monotherapy 250 mg/m\^2 until progression of disease, unacceptable toxicity, or another withdrawal criteria is met.

    Drug: Cetuximab · Drug: Cisplatin · Drug: Carboplatin · Drug: 5-Fluorouracil

Interventions

  • Administered intravenously

    Also known as: Erbitux, LY2939777

  • Administered intravenously

  • Administered intravenously

  • Administered intravenously

    Also known as: 5-FU

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013

    September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality.

    Time frame: Part 2: Baseline to end of combination therapy (up to 18 weeks)

  2. Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013

    January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality.

    Time frame: Part 2: Baseline to end of combination therapy or date first participant switched to US commercial cetuximab (up to 18 weeks)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.

    Time frame: Parts 1 and 2: Randomization to Date of Death from any Cause (Up to 36.3 Months)

  2. Progression-Free Survival (PFS)

    PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.

    Time frame: Parts 1 and 2: Randomization to Progression of Disease or Death from any Cause (Up to 32.7 Months)

  3. Percentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

    Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version \[v\]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)\*100.

    Time frame: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)

  4. Number of Participants With Anti-Cetuximab Antibodies

    Time frame: Day 1, Week 1 of Cycles 3 and 5 (postbaseline samples were collected prior to infusion).

  5. Percentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR)

    Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria.

    Time frame: Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)

  6. Maximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing

    The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy.

    Time frame: Part 2: Cycle 1, Day 1: 0 hours [(h); immediately postdose], 1 h, 2 h, and 24 h postdose

  7. Cmax of Cetuximab at Steady State

    A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m\^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.

    Time frame: Part 2: Weekly from Cycle 1, Week 3 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose

  8. Area Under the Concentration Curve (AUC) of Cetuximab at Steady State

    A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m\^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.

    Time frame: Part 2: Weekly from Cycle 1, Day 1 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose

07

Results

Posted Jul 14, 2014

Participant flow

Participant flow — Overall Study
MilestonePart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU
Started338173
Received at least 1 dose of study drug337771
Completed337771
Not completed042

Outcome measures

PrimaryNumber of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013

September 27, 2013 is the date when data was last collected for the primary endpoint. Prior to this date, the manufacturing process for the BI-manufactured cetuximab was changed necessitating the need to switch participants to US commercial cetuximab. All other components of their treatment regimen remained unchanged and participants stayed in their original reporting group. Therefore, the number of participants in the BI-manufactured cetuximab treatment arm who had TEAEs includes TEAEs while participants received BI-manufactured and US-commercial cetuximab. Using September 27 cut-off, the analysis of TEAEs is confounded by the switch from BI-manufactured to US commercial cetuximab. TEAEs were defined as serious and other non-serious AEs that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-In group available in Reported Adverse Events module which is summary of serious and other non-serious AEs regardless of causality.

Time frame:
Part 2: Baseline to end of combination therapy (up to 18 weeks)
Reported as:
Number · participants
Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 2013
participantsPart 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs); Data Analysis Cut-Off: September 27, 20137668
PrimaryNumber of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013

January 23, 2013 is the date when the first participant in the BI-manufactured cetuximab treatment arm switched to US commercial cetuximab due to changes in the manufacturing process for the BI-manufactured cetuximab necessitating the need to switch participants to US commercial cetuximab. Each participant who switched treatments received at least 2 cycles of BI-manufactured cetuximab before switching. All other components of their treatment regimen remained unchanged. The number of participants who had TEAEs during combination therapy is reported. Using January 23 cut-off, data is un-confounded by lack of BI-manufactured cetuximab. TEAEs were defined as serious and other non-serious adverse events (AEs) that occurred or worsened after study treatment (regardless of causality). TEAE information for Safety Lead-in group available in Reported Adverse Event module which is summary of serious and other non-serious AEs regardless of causality.

Time frame:
Part 2: Baseline to end of combination therapy or date first participant switched to US commercial cetuximab (up to 18 weeks)
Reported as:
Number · participants
Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 2013
participantsPart 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI),
Number of Participants Who Had TEAEs; Data Analysis Cut-Off: January 23, 20137568
SecondaryOverall Survival (OS)

OS was defined as duration from the date of randomization to the date of death from any cause. For each participant not known to have died as of the 23 October 2014 data cutoff date for the analysis, OS was censored at the date last known to be alive. In addition, any participants on Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.

Time frame:
Parts 1 and 2: Randomization to Date of Death from any Cause (Up to 36.3 Months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsPart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Overall Survival (OS)9.13 (6.60 to 10.38)9.23 (6.90 to 11.80)9.46 (6.87 to 11.43)
SecondaryProgression-Free Survival (PFS)

PFS was defined as duration from the date of randomization to the first date of objective progressive disease (PD) or death from any cause. For each participant who was not known to have died or to have had objective PD as of the 23 October 2014 data cutoff date for the analysis, PFS was censored at the date of the participant's last complete tumor assessment prior to that cutoff date. In addition, any participant in Arm B who was switched from BI-manufactured cetuximab to ImClone-manufactured cetuximab was censored at the time of the switch.

Time frame:
Parts 1 and 2: Randomization to Progression of Disease or Death from any Cause (Up to 32.7 Months)
Reported as:
Median · Months
Progression-Free Survival (PFS)
MonthsPart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Progression-Free Survival (PFS)4.57 (3.22 to 5.32)4.34 (3.52 to 5.78)5.59 (4.04 to 6.28)
SecondaryPercentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST, version \[v\]1.0) criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Percentage of participants with a confirmed CR or PR=(number of participants whose best overall response was CR or PR)/(number of participants treated)\*100.

Time frame:
Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
percentage of participantsPart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Percentage of Participants Having a Confirmed Best Response of Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])24.2 (9.6 to 38.9)32.5 (22.0 to 42.9)36.6 (25.4 to 47.8)
SecondaryNumber of Participants With Anti-Cetuximab Antibodies
Time frame:
Day 1, Week 1 of Cycles 3 and 5 (postbaseline samples were collected prior to infusion).
Reported as:
Number · participants
Number of Participants With Anti-Cetuximab Antibodies
participantsAll Participants (Cetuximab)
Number of Participants With Anti-Cetuximab Antibodies4
SecondaryPercentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR)

Response was defined using RECIST, v1.0 criteria. CR was defined as the disappearance of all target lesions. PR was defined as having at least a 30% decrease in sum of longest diameter of target lesions. Progressive Disease (PD) was defined as having at least a 20% increase in the sum of the longest diameter of target lesions. Stable Disease (SD) was defined as small changes that did not meet the above criteria.

Time frame:
Parts 1 and 2: Randomization to Progression of Disease (Up to 32.7 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR)
percentage of participantsPart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Percentage of Participants Having a Best Response of CR, PR, or Stable Disease (SD) - Disease Control Rate (DCR)69.7 (54.0 to 85.4)58.4 (47.4 to 69.4)62.0 (50.7 to 73.3)
SecondaryMaximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing

The Cmax of cetuximab following 400 mg/m² cetuximab dosing during Part 2 of the study is reported. As specified in the protocol, pharmacokinetics (PK) samples were not collected during Part 1 of the study, Safety Lead-In or during Part 2 monotherapy.

Time frame:
Part 2: Cycle 1, Day 1: 0 hours [(h); immediately postdose], 1 h, 2 h, and 24 h postdose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Maximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing
micrograms per milliliter (μg/mL)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Maximum Serum Concentration (Cmax) of Cetuximab Following 400 mg/m² Cetuximab Dosing208 ± 10.2208 ± 7.8
SecondaryCmax of Cetuximab at Steady State

A total of 4 samples were collected at various times during combination therapy, from the third dose of 250 mg/m\^2 cetuximab in Cycle 1 (Week 3) through the final dose in Cycle 3 (Week 3) and used to report Cmax of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.

Time frame:
Part 2: Weekly from Cycle 1, Week 3 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Cmax of Cetuximab at Steady State
micrograms per milliliter (μg/mL)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Cmax of Cetuximab at Steady State225 ± 17.7199 ± 15.3
SecondaryArea Under the Concentration Curve (AUC) of Cetuximab at Steady State

A total of 4 samples were collected during combination therapy, from the first dose of 250 mg/m\^2 cetuximab in Cycle 1 (Day 1) through the final dose in Cycle 3 (Week 3) and used to report AUC of cetuximab at steady state during Part 2 of the study. As specified in the protocol, PK samples were not collected during Part 1 of the study, Safety Lead-In, or during Part 2 monotherapy.

Time frame:
Part 2: Weekly from Cycle 1, Day 1 through Cycle 3, Week 3: 0 h (immediately postdose), 24 h, 96 h, and 168 h postdose
Reported as:
Geometric mean · micrograms*hours/milliliter (μg*h/mL)
Area Under the Concentration Curve (AUC) of Cetuximab at Steady State
micrograms*hours/milliliter (μg*h/mL)Part 2: Combination Therapy: Cetuximab (US Commercial)Part 2: Combination Therapy: Cetuximab (Manufactured by BI)
Area Under the Concentration Curve (AUC) of Cetuximab at Steady State21900 ± 31.818800 ± 25.5

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)—20/33 (60.6%)32/33 (97%)
Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FU—48/77 (62.3%)64/77 (83.1%)
Part 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU—42/71 (59.2%)62/71 (87.3%)
Most frequent serious events
Showing 10 of 125
Most frequent serious events
EventPart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU
DiarrhoeaGastrointestinal disorders6/333/772/71
DehydrationMetabolism and nutrition disorders5/337/779/71
AnaemiaBlood and lymphatic system disorders4/334/775/71
NauseaGastrointestinal disorders4/337/772/71
VomitingGastrointestinal disorders4/337/774/71
FatigueGeneral disorders3/331/771/71
PneumoniaInfections and infestations3/335/775/71
SepsisInfections and infestations3/335/771/71
NeutropeniaBlood and lymphatic system disorders2/336/773/71
Febrile neutropeniaBlood and lymphatic system disorders2/331/775/71
Most frequent other events
Showing 10 of 92
Most frequent other events
EventPart 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FU
NauseaGastrointestinal disorders19/3334/7733/71
AnaemiaBlood and lymphatic system disorders18/3319/7727/71
HypomagnesaemiaMetabolism and nutrition disorders18/3330/7729/71
FatigueGeneral disorders16/3335/7737/71
Dermatitis acneiformSkin and subcutaneous tissue disorders17/3326/7719/71
NeutropeniaBlood and lymphatic system disorders15/3317/7723/71
DiarrhoeaGastrointestinal disorders15/3323/7722/71
VomitingGastrointestinal disorders15/3317/7725/71
HypokalaemiaMetabolism and nutrition disorders14/3317/7723/71
ConstipationGastrointestinal disorders9/3316/7725/71

Baseline characteristics

Participants who received at least 1 dose of any study drug (cetuximab, cisplatin, carboplatin, or 5-FU).

Age, Continuous
Age, Continuous(years)Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FUTotal
Mean62.9 ± 8.7457.1 ± 10.7559.4 ± 10.4959.0 ± 10.47
Sex/Gender, Customized
Sex/Gender, Customized(participants)Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FUTotal
Female1191535
Male226855145
Unknown or Not Reported0011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FUTotal
American Indian or Alaska Native216927
Asian0123
Black or African American27211
White295356138
More than 1 race0011
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(participants)Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FUTotal
United States27252880
Mexico1231539
Canada5292761
Disease Stage at Study Entry
Disease Stage at Study Entry(participants)Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FUTotal
Locoregional6343272
Metastatic274338108
Unknown or not reported0011
Karnofsky Performance Status (KPS)
Karnofsky Performance Status (KPS)(participants)Part 1: Safety Lead-In (Cetuximab, Cis or Carbo, 5-FU)Part 2: Cetuximab (US Commercial), Cis or Carbo, 5-FUPart 2: Cetuximab (Manufactured by BI), Cis or Carbo, 5-FUTotal
KPS 7059721
KPS 8019282269
KPS 905323168
KPS 100481123
08

Study locations

26 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucson, Arizona 85715, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fullerton, California 92835, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Long Beach, California 90813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grand Junction, Colorado 81501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Weston, Florida 33331, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, Georgia 31701, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chicago, Illinois 60612, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Illinois 62703, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New Albany, Indiana 47150, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wichita, Kansas 67214, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albany, New York 12208, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    New York, New York 10029, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Portland, Oregon 97207, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Charleston, South Carolina 29425, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Abilene, Texas 79606, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2N 4N2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Edmonton, Alberta T6G 1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, Ontario N6A 4L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ottawa, Ontario K1H 8L6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M5G 2M9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, Quebec H2L 4M1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chihuahua, 31000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Guadalajara, 44200, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Merida, 97000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mexico City, 14000, Mexico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Monterrey, 64320, Mexico
09

References and documents

Publications

  • Soulieres D, Aguilar JL, Chen E, Misiukiewicz K, Ernst S, Lee HJ, Bryant K, He S, Obasaju CK, Chang SC, Chin S, Adkins D. Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen. BMC Cancer. 2016 Jan 14;16:19. doi: 10.1186/s12885-016-2064-0. PubMed 26768732 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Aug 2013 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2010
First posted
Mar 5, 2010
Start
Jun 2010
Primary completionActual
Aug 2013
CompletionActual
Sep 2015
Results first posted
Jul 14, 2014
Last update
Sep 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01081041
Responsible party
Sponsor
First posted
Mar 5, 2010
Start date
Jun 2010
Primary completion
Aug 2013
Completion
Sep 2015
Results posted
Jul 14, 2014
Last update
Sep 25, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Cisplatin · Carboplatin · Fluorouracil

Start the discussion